Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Total Liabilities (2021 - 2025)

ARS Pharmaceuticals' Total Liabilities history spans 5 years, with the latest figure at $213.4 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 126.16% year-over-year to $213.4 million; the TTM value through Dec 2025 reached $213.4 million, up 126.16%, while the annual FY2025 figure was $213.4 million, 126.16% up from the prior year.
  • Total Liabilities for Q4 2025 was $213.4 million at ARS Pharmaceuticals, down from $225.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $225.1 million in Q3 2025 and bottomed at $2.4 million in Q4 2023.
  • The 5-year median for Total Liabilities is $15.9 million (2022), against an average of $46.4 million.
  • The largest annual shift saw Total Liabilities crashed 80.47% in 2022 before it surged 3786.12% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $16.7 million in 2021, then tumbled by 48.73% to $8.5 million in 2022, then crashed by 71.6% to $2.4 million in 2023, then soared by 3786.12% to $94.4 million in 2024, then surged by 126.16% to $213.4 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Total Liabilities are $213.4 million (Q4 2025), $225.1 million (Q3 2025), and $121.2 million (Q2 2025).